

### Remarks

This amendment is made in response to the Office Action dated September 26, 2005. By this amendment, claims 7, 12 and 16 have been amended so as to be in independent form, and any further amendments have been made to ensure that all pending claims depend therefrom.

Claims 1-4, 6, 11 and 13-15 currently stand rejected under 35 U.S.C. § 103 as being unpatentable over U.S. Patent No. 4,905,691 ("Rydell") in view of U.S. Patent No. 5,782,839 ("Hart"). Claim 5 currently stands rejected under 35 U.S.C. § 103 as being unpatentable over the combination of Rydell and Hart in view of U.S. Patent No. 4,905,691 ("Desai"). Claims 7-10, 12, 16 and 17 have been indicated by the Examiner as being allowable if rewritten in independent form.

By this Amendment, applicants have amended independent claims 7, 12 and 16 be in independent form incorporating all limitations from claim(s) from which they depend. Claims 1 and 14 have been canceled, and all remaining claims have been amended to ensure dependence from one of amended independent claims 7, 12 and 16.

In view of the foregoing, applicants believe that the Examiner's rejections and objections have been fully overcome, and that each of pending claims 2-13 and 14-17 are currently in condition for allowance, which is respectfully requested.

Applicants believe that no fee is due in connection with this response. The Commissioner is hereby authorized, however, to charge any additional fees that may be required to Account No. 10-0750/GYN-5009/MJS. This Authorization is being submitted in triplicate.

Respectfully submitted,  
/Melissa J. Szanto/

Melissa J. Szanto  
Attorney for the Applicants  
Reg. No. 40,834

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1365  
DATED: December 5, 2005

s/n 10/674,453